Drug Profile


Alternative Names: CMI CSX-1A; CMI X-11A; DCA I.V.

Latest Information Update: 19 Aug 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Alberta
  • Developer Valens Pharma
  • Class Acetates; Adjunct therapies; Cardiovascular therapies; Chlorinated hydrocarbons
  • Mechanism of Action Pyruvate dehydrogenase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Reperfusion injury

Most Recent Events

  • 19 Aug 2008 qc
  • 05 Aug 2008 Suspended - Phase-II for Reperfusion injury in Canada (IV)
  • 28 Jul 2008 Valens Pharma completes phase II trial in reperfusion injury in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top